Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Press

Showing results (171-180 of 273) with videos related to

Pageof 28
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 29, 2008
Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancerAngelo Di Leo, Henry L Gomez, Zeba Aziz, et al.
Journal of the National Cancer Institute|May 20, 2004
Results of two open-label, multicenter phase II studies of docetaxel, platinum salts, and trastuzumab in HER2-positive advanced breast cancerMark D Pegram, Tadeusz Pienkowski, Donald W Northfelt, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 30, 2009
Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancerStephen Johnston, John Pippen, Xavier Pivot, et al.
Geburtshilfe Und Frauenheilkunde|January 5, 2024
RANK and RANKL Expression in Tumors of Patients with Early Breast CancerAnnika Behrens, Lena Wurmthaler, Felix Heindl, et al.
Nature Cancer|December 30, 2021
Spatial proteomic characterization of HER2-positive breast tumors through neoadjuvant therapy predicts responseKatherine L McNamara, Jennifer L Caswell-Jin, Rohan Joshi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 17, 2005
Diagnostic evaluation of HER-2 as a molecular target: an assessment of accuracy and reproducibility of laboratory testing in large, prospective, randomized clinical trialsMichael F Press, Guido Sauter, Leslie Bernstein, et al.
Cancer Medicine|May 1, 2015
Reduced risk of breast cancer associated with recreational physical activity varies by HER2 statusHuiyan Ma, Xinxin Xu, Giske Ursin, et al.
Breast Cancer Research : BCR|January 24, 2018
Body mass index at age 18 years and recent body mass index in relation to risk of breast cancer overall and ER/PR/HER2-defined subtypes in white women and African-American women: a pooled analysisHuiyan Ma, Giske Ursin, Xinxin Xu, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|May 17, 2006
Relationship between established breast cancer risk factors and risk of seven different histologic types of invasive breast cancerChristopher I Li, Janet R Daling, Kathleen E Malone, et al.
BMC Cancer|May 7, 2013
Mortality risk of black women and white women with invasive breast cancer by hormone receptors, HER2, and p53 statusHuiyan Ma, Yani Lu, Kathleen E Malone, et al.
Pageof 28

Showing results (171-180 of 273) with videos related to

Sort By:
Pageof 28
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 29, 2008
Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancerAngelo Di Leo, Henry L Gomez, Zeba Aziz, et al.
Journal of the National Cancer Institute|May 20, 2004
Results of two open-label, multicenter phase II studies of docetaxel, platinum salts, and trastuzumab in HER2-positive advanced breast cancerMark D Pegram, Tadeusz Pienkowski, Donald W Northfelt, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 30, 2009
Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancerStephen Johnston, John Pippen, Xavier Pivot, et al.
Geburtshilfe Und Frauenheilkunde|January 5, 2024
RANK and RANKL Expression in Tumors of Patients with Early Breast CancerAnnika Behrens, Lena Wurmthaler, Felix Heindl, et al.
Nature Cancer|December 30, 2021
Spatial proteomic characterization of HER2-positive breast tumors through neoadjuvant therapy predicts responseKatherine L McNamara, Jennifer L Caswell-Jin, Rohan Joshi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 17, 2005
Diagnostic evaluation of HER-2 as a molecular target: an assessment of accuracy and reproducibility of laboratory testing in large, prospective, randomized clinical trialsMichael F Press, Guido Sauter, Leslie Bernstein, et al.
Cancer Medicine|May 1, 2015
Reduced risk of breast cancer associated with recreational physical activity varies by HER2 statusHuiyan Ma, Xinxin Xu, Giske Ursin, et al.
Breast Cancer Research : BCR|January 24, 2018
Body mass index at age 18 years and recent body mass index in relation to risk of breast cancer overall and ER/PR/HER2-defined subtypes in white women and African-American women: a pooled analysisHuiyan Ma, Giske Ursin, Xinxin Xu, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|May 17, 2006
Relationship between established breast cancer risk factors and risk of seven different histologic types of invasive breast cancerChristopher I Li, Janet R Daling, Kathleen E Malone, et al.
BMC Cancer|May 7, 2013
Mortality risk of black women and white women with invasive breast cancer by hormone receptors, HER2, and p53 statusHuiyan Ma, Yani Lu, Kathleen E Malone, et al.
Pageof 28